B-Cell Chronic Lymphocytic Leukemia (DBCOND0030547)

Identifiers

Synonyms
Lymphocytic Leukemia, Chronic, B-Cell / Lymphocytic Leukemia, Chronic, B Cell / Leukemia, Chronic Lymphocytic, B-Cell / B-cell chronic lymphocytic leukemia (CLL) / B-Cell Chronic Lymphocytic Leukemia (B-CLL) / B-cell chronic lymphocytic leukemia / Leukemia, Lymphocytic, Chronic, B-Cell / Chronic B Cell Lymphocytic Leukemia / Chronic Leukemia, Lymphocytic, B Cell / Chronic lymphocytic leukemia of B-cell type not having achieved remission / Chronic lymphocytic leukemia of B-cell type / B-cell chronic lymphocytic leukaemia / Chronic lymphocytic leukemia / Leukemia lymphocytic chronic / CLL / Chronic lymphoid leukaemia / Lymphoid leukaemia, chronic / Chronic lymphoid leukemia, disease (disorder) / Lymphoid leukemia, chronic / Chronic lymphatic leukaemia / Chronic lymphoid leukemia / Leukaemia lymphocytic chronic / Chronic lymphatic leukemia / Chronic lymphocytic leukaemia NOS / Leukaemias chronic lymphocytic / Chronic lymphocytic leukaemia / Chronic lymphocytic leukemia, morphology (morphologic abnormality)

Associated Data

Indicated Drugs and Targets
DrugDescriptionTargets
Alemtuzumab
A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis.
Human immunoglobulin G
A purified form of human immunoglobulin G and other proteins used to treat immunodeficiency and a wide variety of autoimmune disorders.
Clinical Trials
IdentifierTitleDrug(s)PurposePhaseStatus
NCT03204188
Ibrutinib, Fludarabine, and Pembrolizumab in High-Risk or Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment2active_not_recruiting
NCT01370772
Intensified Rituimab Prephase Before FCR in Untreated B-CLLtreatment2completed
NCT00328198
Subcutaneous Alemtuzumab (CAMPATH®, MabCampath®) in Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemiatreatment2completed
NCT01612988
Treatment With Bendamustine, Ofatumumab and MethylPrednisolone in Relapsed B-CLLNo drug interventionstreatment2terminated
NCT03331198
Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)treatment1 / 2recruiting
NCT03462719
A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)treatment3active_not_recruiting
NCT04210219
A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaNo drug interventionstreatment1active_not_recruiting
NCT05024045
Study of Oral LOXO-338 in Patients With Advanced Blood Cancerstreatment1active_not_recruiting
NCT05645107
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants with HGG and Recurrent or Severe Infections Associated with B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphomatreatment3recruiting
NCT05947851
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010)treatment3recruiting
NCT03900598
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1active_not_recruiting
NCT04540796
A Study of JNJ-75348780 in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1active_not_recruiting
NCT04876092
A Study of the MALT1 Inhibitor JNJ-67856633 and Ibrutinib in Combination in B-cell NHL and CLLtreatment1active_not_recruiting
NCT05424822
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)No drug interventionstreatment1recruiting
NCT05963074
A Study to Customize Ibrutinib Treatment Regimens for Participants With Previously Untreated Chronic Lymphocytic Leukemiatreatment2recruiting
NCT06299540
Benefits of Individual Physical Activity Intervention on Health-related Quality of Life in Participants With Chronic Lymphocytic LeukemiaNot AvailableNot Availablerecruiting
NCT02298816
B-Cell Hematologic Malignancy Vaccination RegistryNo drug interventionsNot AvailableNot Availablewithdrawn
NCT05797233
Trial of Anti-CD19 and Anti-CD20 Bicistronic Chimeric Antigen Receptor T Cells for Treating B-Cell Malignanciestreatment1active_not_recruiting
NCT05094206
CAR20.19.22 T-cells in Relapsed, Refractory B-cell MalignanciesNo drug interventionstreatment1terminated
NCT06364423
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)treatment1 / 2recruiting
NCT01126502
Alvespimycin Hydrochloride in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic Leukemiatreatment1terminated
NCT01005979
A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)treatment1terminated
NCT02782351
Humanized CAR-T Therapy for Treatment of B Cell MalignancyNo drug interventionstreatment1 / 2unknown_status
NCT01105247
Safety of PCI-32765 in Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT00774345
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapytreatment3completed
NCT01258998
Study of Akt Inhibitor MK2206 in Patients With Relapsed LymphomaNo drug interventionstreatment2completed
NCT00101205
Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphomatreatment1terminated
NCT00927797
Interventional Study on Pentostatin, Cyclophosphamide and Rituximab in Indolent B-Cell Non-Hodgkin-Lymphoma (B-NHL)treatment2unknown_status
NCT00302861
A Study to Evaluate the Treatment of Previously Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL)No drug interventionsNot Available1 / 2terminated
NCT03720561
A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World SettingNot AvailableNot Availablecompleted
NCT03343678
This Study in Patients With Chronic Lymphocytic Leukaemia is Done to Determine a Safe and Effective Dose of BI 836826 in Combination With Venetoclaxtreatment1withdrawn
NCT01576588
Rituximab in Pretreated Elderly or Unfit B-CLL Patientstreatment2completed
NCT03301207
A Study to Evaluate the Effect of Ibrutinib on the Pharmacokinetics of Oral Contraceptives, CYP2B6, and CYP3A4 Substrates in Female Participants With B Cell Malignancyother1completed
NCT00771056
Hydroxychloroquine in Untreated B-CLL Patientstreatment2terminated
NCT01400685
Lenalidomide Plus Bendamustine and Rituximab for Untreated CLL/SLLtreatment1completed
NCT02440685
A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumorstreatment1 / 2terminated
NCT03757000
A Phase I Study of YY-20394 in Patients With B Cell Hematologic MalignanciesNo drug interventionstreatment1unknown_status
NCT04271800
Safety and Efficacy of CD19-Targeted CAR-T Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaNo drug interventionstreatment1 / 2recruiting
NCT01982175
Phase II Clinical Trial of Alemtuzumab to Treat B-cell Chronic Lymphocytic Leukemiatreatment2suspended
NCT05244070
A Study to Evaluate the Safety and Tolerability of BMS-986403 in Participants With Relapsed and/or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1terminated
NCT00098670
Fludarabine, Rituximab, and Alemtuzumab in Treating Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT02454270
A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignanciestreatment1terminated
NCT02685670
Competitive Transfer of αCD19-TCRz-CD28 and αCD19-TCRz-CD137 CAR-T Cells for B-cell Leukemia/Lymphomatreatment1 / 2unknown_status
NCT02406742
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment1 / 2completed
NCT02733042
A Study to Determine Dose, Safety, and Efficacy of Durvalumab as Monotherapy and in Combination Therapy in Subjects With Lymphoma or Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT00005799
Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney CancertreatmentNot Availablecompleted
NCT00336206
Low Dose Alemtuzumab for Consolidation and Maintenance of Patients With B-Cell Chronic Lymphocytic LeukemiatreatmentNot Availableunknown_status
NCT05515406
A Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of ONO-7018 in Patients With R/R NHL or CLLNo drug interventionstreatment1recruiting
NCT02213913
Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomastreatment1 / 2active_not_recruiting
NCT05259813
Phase I Study of JWCAR029 in Subjects With R/R CLL/SLLNo drug interventionstreatment1withdrawn
NCT01158118
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donorstreatment2completed
NCT02437019
Early Access Program (EAP) for Ibrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Not AvailableNot Availableapproved_for_marketing
NCT03265717
DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (hTERT), Invac-1 in Chronic Lymphocytic Leukemiatreatment2terminated
NCT04849416
A Study of LOXO-305 in Chinese Participants With Blood Cancer (Including Lymphoma and Chronic Leukemia)treatment2active_not_recruiting
NCT02759016
Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinibtreatment1completed
NCT00626496
Family Study of Lymphoproliferative DisordersNo drug interventionsNot AvailableNot Availablerecruiting
NCT01292135
Safety and Tolerability Study of PCI-32765 Combined With Fludarabine/Cyclophosphamide/Rituximab (FCR) and Bendamustine/Rituximab (BR) in Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT00058786
Treatment of Chronic Lymphocytic B-Leukemia With IL-2 and CD-40 Autologous Tumor CellsNo drug interventionstreatment1completed
NCT02757586
Treatment of Chronic Lymphocytic LeukemiaNo drug interventionsNot AvailableNot Availableunknown_status
NCT00344786
Phase 1, Dose-Escalation Study of Oral CNF2024(BIIB021) in CLLtreatment1terminated
NCT00648739
Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMtreatment1 / 2terminated
NCT00768339
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomastreatment1 / 2terminated
NCT02336048
A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbiditiestreatment1terminated
NCT00951457
Bendamustine Combined With Alemtuzumab in Pretreated Chronic Lymphocytic Leukemia (CLL)treatment1 / 2completed
NCT03151057
Idelalisib Post Allogeneic Hematopoietic Stem Cell Transplant (HSCT) in B Cell Derived Malignanciestreatment1terminated
NCT01744626
Safety Study of CC-292 and Rituximab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphomatreatment1completed
NCT00006226
Thalidomide in Treating Patients With Relapsed Chronic Lymphocytic Leukemiatreatment2completed
NCT00003620
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT03289182
An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)Not AvailableNot Availablecompleted
NCT01110473
ABT-348 as Monotherapy and in Combination With Azacitidine to Treat Advanced Hematologic Malignanciestreatment1completed
NCT00058227
Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphomatreatment1completed
NCT03502876
Tolerance and Resistance to Ibrutinib in Patients With Chronic Lymphocytic Leukemia (CLLNo drug interventionsNot AvailableNot Availablecompleted
NCT00089076
MDX-010 in Treating Patients With Recurrent or Refractory Lymphomatreatment1 / 2terminated
NCT01144260
Study of Bafetinib as Treatment for Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL)treatment2completed
NCT01649791
Lenalidomide as Chemoprevention in Treating Patients With High-Risk, Early-Stage B-Cell Chronic Lymphocytic LeukemiatreatmentNot Availableterminated
NCT01212380
Study of Carfilzomib in Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL) or Prolymphocytic Leukemia (PLL)treatment1completed
NCT00086580
Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patientstreatment3completed
NCT01373229
Lenalidomide + Plerixafor in Previously Treated Chronic Lymphocytic Leukemia (CLL)treatment1completed
NCT01864889
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19No drug interventionstreatmentNot Availableunknown_status
NCT03746392
Project to Improve Communication About Serious Illness - Pilot StudyNo drug interventionssupportive_careNot Availablecompleted
NCT00058240
Flavopiridol in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia or Lymphocytic Lymphomatreatment1 / 2completed
NCT03110640
Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphomatreatment1unknown_status
NCT01735604
Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to ChemotherapyNo drug interventionstreatment1 / 2unknown_status
NCT00377104
Alvocidib in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment1terminated
NCT02361346
Safety, PD & Efficacy of MT-3724 for the Treatment of Patients With Relapsed or Refractory DLBCLNo drug interventionstreatment1 / 2terminated
NCT02743546
Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Duvortuxizumab (JNJ-64052781) Plus Ibrutinib in Lymphomatreatment1withdrawn
NCT00697346
Study of MLN8237 in Participants With Advanced Hematological Malignanciestreatment1completed
NCT00398112
Sunitinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphomatreatment2completed
NCT00290810
Bevacizumab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment2completed
NCT00861510
A Pilot Study of the Safety and Activity of Escalating Doses of ON 01910.Na in Patients With Relapsed Mantle Cell Lymphoma, Multiple Myeloma, Chronic Lymphocytic Leukemia, and Related Lymphoid Malignanciestreatment1completed
NCT00565981
A Pilot Trial With Subcutaneous Alemtuzumab and Oral Fludarabinephosphate for the Determination of Safety, Efficacy and Molecular Profiling for the Prediction of Responsetreatment2completed
NCT04160195
T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphomatreatment1terminated
NCT04030195
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLLtreatment1 / 2completed
NCT00545714
A Study to Assess the Efficacy of Rituximab (MabThera) in First Line Treatment of Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT03476655
Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaNot AvailableNot Availablecompleted
NCT00918450
Study Assessing the Safety and Efficacy of ABT-263 in Subjects With B-cell Chronic Lymphocytic Leukemia (CLL) Who Have Failed at Least One Prior Fludarabine-containing Regimentreatment2withdrawn
NCT00800943
Study of Subcutaneous Campath-1H in Patients With B-Cell CLL and Residual Disease After Chemotherapytreatment2unknown_status
NCT06205290
A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapiestreatment3withdrawn
NCT00201721
Pentostatin, and Rituximab With and Without Cyclophosphamide for Previously Untreated B-Chronic Lymphocytic Leukemiatreatment2completed
NCT02846584
a Clinical Research of Sequential CAR-T Bridging HSCT in the Treatment of Relapse/Refractory B-cell MalignanciesNo drug interventionstreatment2unknown_status
NCT00435084
A Phase I/II Study to Assess the Safety and Tolerability of APO866 for the Treatment of Refractory B-CLLtreatment1 / 2completed
NCT02912754
Ruxolitinib Combined With Ibrutinib in Chronic Lymphocytic Leukemia Patientstreatment1 / 2unknown_status
NCT00224354
Lymphocytic B-Leukemia (B-CLL) w/Human IL-2 Gene Modified & Human CD40 Ligand-Expressing Autologous Tumor Cellstreatment1withdrawn
NCT03755947
Ibrutinib, Obinutuzumab and Venetoclax for Patients With Chronic Lymphocytic Leukemiatreatment2completed
NCT02666898
Phase II Trial GA101 Inbrutinib B CLLtreatment2completed
NCT00046683
Efficacy/Safety of Frontline Alemtuzumab (Campath, MabCampath) vs Chlorambucil in Patients With Progressive B-Cell Lymphocytic Leukemiatreatment3completed
NCT01732861
Safety Study of CC-292 and Lenalidomide in Subjects With Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphomatreatment1completed
NCT00220311
A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopeniatreatment4completed
NCT00098371
Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemiatreatment2terminated
NCT03088878
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignanciestreatment1 / 2active_not_recruiting
NCT00098488
17-N-Allylamino-17-Demethoxygeldanamycin With or Without Rituximab in Treating Patients With Relapsed B-Cell Chronic Lymphocytic Leukemia or Prolymphocytic Leukemiatreatment1terminated
NCT02168907
CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomatreatment1terminated
NCT02037256
Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple MyelomatreatmentNot Availablecompleted
NCT01269385
Imprime PGG, Alemtuzumab, and Rituximab in Treating Patients With High Risk Chronic Lymphocytic Leukemiatreatment1 / 2completed
NCT01296932
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)treatment1completed
NCT00621452
Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphomatreatment1completed
NCT05172700
Expanded Access Program for Pirtobrutinib for Participants With B-Cell CancerNot AvailableNot Availableavailable
NCT03097770
Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20No drug interventionstreatment1 / 2completed
NCT01217749
Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLtreatment1 / 2completed
NCT02315118
Pilot Study of Autologous T Lymphocytes With ADCC in Patients With CD20-Positive B-Cell Malignanciestreatment1 / 2unknown_status
NCT00321724
AZD2171 in Treating Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemiatreatment2completed
NCT00254163
Fludarabine, Cyclophosphamide, and Rituximab Versus Pentostatin, Cyclophosphamide, and Rituximab in Previously Untreated or Treated B-Cell Chronic Lymphocytic Leukemia Patientstreatment3completed
NCT00871663
Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6)treatment1completed
NCT03685786
CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCTtreatment1unknown_status
NCT03190330
A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletionother4completed
NCT04204057
Efficacy and Safety of Tenalisib (RP6530) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)treatment2completed
NCT00206726
Alemtuzumab/Fludarabine for Relapsed/Refractory B-cell Chronic Lymphocytic Leukemia (B-CLL)treatment2completed
NCT00485966
Study Evaluating Effects of CX-3543 in Patients With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemiatreatment2withdrawn
NCT01029366
CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapytreatment1completed
NCT00646165
Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemiatreatment1terminated
NCT01456182
Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic LeukemiaNo drug interventionsNot Available1withdrawn
NCT00923182
A Safety Confirmatory Study of Alemtuzumab in Japanese Patients With Relapsed or Refractory Chronic Lymphocytic Leukemiatreatment1completed
NCT01604031
Treatment of B-CLL With Autologous IL2 and CD40 Ligand-Expressing Tumor Cells + Lenalidomidetreatment1terminated
NCT03425591
A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeNot AvailableNot Availablecompleted
NCT02381080
Interaction Study of Ibrutinib and Cytochrome P450 (CYP) 3A Inhibitors in Participants With B-cell Malignancytreatment1completed
NCT02869529
Institut Paoli Calmettes Chronic Lymphatic Leukemia DatabaseNo drug interventionsNot AvailableNot Availablerecruiting
NCT00738829
Lenalidomide Dose Escalation Combined With Rituximab/Fludarabine in Untreated CLLtreatment1 / 2completed
NCT02842229
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic NeoplasmsNo drug interventionsNot AvailableNot Availablecompleted
NCT00867529
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphomatreatment2completed
NCT00119392
Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphomatreatment2completed
NCT02757040
Combination of Ibrutinib and As2O3 in the Treatment of CLLtreatment3unknown_status
NCT00288067
Fenretinide and Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphomatreatment1 / 2terminated
NCT00147901
Fludarabine, Cyclophosphamide, and Alemtuzumab in Patients With B-cell Chronic Lymphatic Leukemia (B-CLL)treatment2completed
NCT05888701
"Don't Eat me" Signal in Hematological Malignancies: CD24 as New Target to Improve Anti-cancer Immunity.No drug interventionsNot AvailableNot Availablerecruiting
NCT00845104
Fludarabine Phosphate, Rituximab, and Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia That Has Relapsed or Not Responded To Treatmenttreatment2withdrawn
NCT00290472
CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemiatreatment2completed
NCT01109069
Safety and Tolerability Study of PCI-32765 in B Cell Lymphoma and Chronic Lymphocytic Leukemiatreatment2completed
NCT02556346
Pharmacokinetics (PK), Pharmacodynamics (PD), Safety, Tolerability of Multiple Dose Regimens of MT-3724 for the Treatment of Patients With Relapsed Chronic B-cell Lymphocytic Leukemia or Small Lymphocytic LymphomaNo drug interventionstreatment1withdrawn
NCT00871546
SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)treatment2terminated
NCT00612612
Obatoclax, Fludarabine, and Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemiatreatment1terminated
NCT00910910
Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)treatment3completed
NCT04271410
CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and LymphomaNo drug interventionstreatment1 / 2recruiting
NCT02639910
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKitreatment2completed
NCT00558181
High-dose Methylprednisolone and Rituximab in High Risk B-CLLtreatment2completed
NCT01789255
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignanciessupportive_care2completed
NCT04290923
Determination of Blood Tumor CellsNo drug interventionsNot AvailableNot Availablecompleted
NCT05650723
Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obinutuzumabtreatment2recruiting
NCT03420183
A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignanciestreatment1 / 2recruiting